{"name":"Scholar Rock, Inc.","slug":"scholar-rock-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":208440000,"netIncome":-377939000,"cash":323527000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxORHVleGc4Rzl1NEJnU3N0c2Y4ME9Ea0djNFlPWXZrWGJIMEk0Q1pRUE9YYUVMbWdHWEdla21TdmRSSXlHbGJuem5wX2QxUG82bS1Bd1pkM29ZaEZRUEYtMHhsV2tsd0s3eElNazlkdDNYU3hQRmpvRUJycGxhNEZnSmItaXpWMDh2eGxoZ0VDV1BQRHpZNy1oNHh3M1FUOWx5VERKUDZwZk5lUkhPaFlLWFI2Z3hWTjJqX3dZdkVWbWt6YmFzZ2JsYm5HOA?oc=5","date":"2026-04-02","type":"pipeline","source":"Sahm","summary":"Scholar Rock To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday - Sahm","headline":"Scholar Rock To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNZ3BXdEJndXFXTWVwU1R3dWdQUmtCNi1Yamo1SUJLMjdGQkZvY3ZGUFdtbG9GOEtfbHBLRGFGOGtXNE9NMDZfd1dEM3A1enFTMktIemNNVFdBY3NDeTU3eDZCMFVCRElZMFVaT2V6a0dLNWlYbm1uNmhzQlNIbFZ4TS02UUpPWVdIQTluLWJKN0NxMENfeDg4aGhrUks0RlJOTFdlNC1DRFRsNE45WXdnaUZoR2VjMXpMNG5uUGFoNnM?oc=5","date":"2026-04-01","type":"pipeline","source":"Reuters","summary":"Weight-loss drug developers line up to tap lucrative market as competition heats up - Reuters","headline":"Weight-loss drug developers line up to tap lucrative market as competition heats up","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNSFRFa1lYYmRtdVFVeGJNWXlYUDRvdms5eG5Db2docnJlWjhwZU1vS1VwQ0NLU0xTbktZSFlRTlAtNTEzRXVXRUVrRlotcFNodnVBT0lfX2FHdFNhZEFNOXE1aHVmbTQ5d2dETklRYkpDSzRsd1dYSWtZUWdlOVJkei0wY0ZvWlNSSlVPQ0dn?oc=5","date":"2026-03-31","type":"regulatory","source":"StocksToTrade","summary":"Scholar Rock Leads with FDA-backed Momentum for 2026 - StocksToTrade","headline":"Scholar Rock Leads with FDA-backed Momentum for 2026","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxOcW1QcjBfb2FyeHJlLXBKSGlGc3hSSGRZMVNTWXY4aGJFLUtzb25wQ0hPb1JQbVl5dFY0UHNXNmR0TGQzVnd3b3JoRC0teXRYM3U0ZERQb182RU95VHJmRXRmbzRranUtYXFDNTV4OWl6MzVkcjdQTHl0SVdRbnRHM3g1Ti1aRVVpd1cteVY3YVdhMks4Wm1NbGlkM09wRHBNTEM2aGJ3VDNrRUxwbGlfdW1hRU1HUjVfVS1iQ2lsNHM3aWV0QXZ1QXo5VnlkRzhGaHpVdDh6cjZUazRRT0VRMTVsZlhKdVZKS084SEhYcklzMFJMNXI4ellXVk9YejhzbDM4X3p4TS1BQ2hjY3Fib2lYTTVyVEtRdEJBY19hLW5fZmRXbWlOZVluTnp4UDJCY3NRcEJ2WUl3T0VtcDViSXlERmZBNXhhTEM1N3hlSQ?oc=5","date":"2026-03-26","type":"regulatory","source":"Barchart.com","summary":"Spinal Muscular Atrophy Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Genentech, Chugai Pharma, Cytokinetics, Ionis Pharma, Genzyme Corp - B","headline":"Spinal Muscular Atrophy Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by Delve","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNRFdnU1ZyYnVrTC14Tlk0b2t6TmF0aU1wcTdnX01YTU1qNm9UVDZObVpRV0ZGQjFCX2ZyYk1RWUNHS0ZVQktQa2JlM2g2YTg0YWZvSjdfY1VfUFQ0M1JHWFZCeUVEYXUweUdlQWFETjlsZDByekU4cklJUEdfTjZ4cHY5MFNFSHFSLVlBVTNETzRTelN0Y3NmZUhTbWpOdw?oc=5","date":"2026-03-25","type":"trial","source":"openPR.com","summary":"Spinal Muscular Atrophy Clinical Trial Pipeline Expands as 18+ - openPR.com","headline":"Spinal Muscular Atrophy Clinical Trial Pipeline Expands as 18+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxOM2JzMUsyRDJ1UHZubDVKVlVTRTI0amtqejdRLTdvLWRnYnM1MDFyWmVqR3ZrMnhxbnJoWGNLaHg2YklYZzR3aUpRTWh4SlJSUXM1QnRaNjdGLTFZYkhOaHl3eUkzaTgtNkhaVXdrZEFSWTdabFlwbmlYdVFMTzNYdlhsak9fNTU1NUx2Q2VjTHRmZUZBWjJLUWtmSUFQQ0hLNlI0RWVvRDZ1dW5oWjVqN3EtWHhkVm5aSkNCUDdUWFRNOGVBUVF2Mnc4dXRDU01YT2JoeWcySHNUV1JweGVjT0NuTExrNUgtakdwa1pQaFM3c3lvZmRPLWVEMEFMMDg?oc=5","date":"2026-03-21","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Are Bullish on These Healthcare Stocks: Viatris (VTRS), Scholar Rock Holding (SRRK) - The Globe and Mail","headline":"Analysts Are Bullish on These Healthcare Stocks: Viatris (VTRS), Scholar Rock Holding (SRRK)","sentiment":"neutral"},{"date":"2026-03-03","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPUkNMWThnUGxOY1JZeTZ6dGZHbWMtUHMwWC1pYTgwdThOYzQ5ZFRvM2FyWmlfeHF6aG5XaGtiSWtINkpST0loZTVXOWNMTXhmeGtWRUlFSUNoMDdlUWE3dEhpMGZUcDVCMDVodUVvVGZScmwwcWlSODZZQ3lFVXdsQlBNcWpTWVlKYm5Bd3VkOE9UYXM4WlZtX1RlMkhRRmZzQ1d3NS1mdjZvcGhE?oc=5","date":"2025-09-23","type":"regulatory","source":"Fierce Pharma","summary":"FDA rejects Scholar Rock's SMA drug, citing issues at Novo's Catalent Indiana site - Fierce Pharma","headline":"FDA rejects Scholar Rock's SMA drug, citing issues at Novo's Catalent Indiana site","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxPd2RTZW5WNmxXcGZ5a05kM1p1bXFzNXJLMV8tb1ROVVF2S0NPUzcyY1h6OFlYd0xGaENFdklsZEk2OUpFdC0wajN2ZWVRNUhwT0l6anc0SnpaeHdIakp3bmZxWGhkT194TEZCal9zVU5qRHJXOE9YWUZwN3ctd1FEOElmX2xKdURrN0R1UXEyclA0ZWNOSWpEOU9nbDZfTW5oZXU2bXlic0Q1b1QyT3hGWmd1N2FFSGozREFwUXQySHFQR2NoT081Yk5R?oc=5","date":"2025-09-23","type":"regulatory","source":"Reuters","summary":"US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall - Reuters","headline":"US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNZGZCaENKdzc0UTdLSFRORWdEWUwtTjc4b0htbkttYldpaDVDTTlYUWhxTXFZa0sxWjBYcURySjFtMERKcUt2QkRrYlI4cHZFZ0dKdG1PcDZRNDA1b3VHMTdHZDRVenl5V0Z1ZWpSeWtDUmR3M1A3cllONFZYTUhBOTlEOExQQnhkRDRVNFRYQnl5WjZhQmdlbWpwZGV3Z3FYb1lJM3doTUdwd3dreERwWDA0aUU1NE0?oc=5","date":"2025-09-23","type":"regulatory","source":"BioPharma Dive","summary":"Scholar Rock SMA drug rejected by FDA over manufacturing concerns - BioPharma Dive","headline":"Scholar Rock SMA drug rejected by FDA over manufacturing concerns","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPZTM3V3kxM1M5QUZ0WjVfaXNMTTJOVFBjY2g0RXdsR3FMVHF3bFdIb0ZjSzR2cnc1enVKVF9nYXF5QUVjaWYyWVlxZTVVYkxQVWxaLTZhYkx4Nk9PeE1PZDN3TUlwVkc0OEVlLU5XcG9uMnotQ1JRWEJTUWFfNm1STUl3dkRZRVNWOUJzdHZaQnZMdGVPOGloUTh5SlV5OGRPZFF5RUprTkFCRVFHYkE?oc=5","date":"2025-09-23","type":"pipeline","source":"BioWorld News","summary":"Another Catalent Indiana delay: Scholar Rock gets CRL for apitegromab - BioWorld News","headline":"Another Catalent Indiana delay: Scholar Rock gets CRL for apitegromab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPdzBDRWJ4Q2pzb202Q0c0YjRKX1Y3ekxQRHR2a3N3U2Y3a0VudUlfZFhjcFBESmZqblpOVkt6cGVnRXZ6R2JqbExKcVlEUWt4b005cnF0X1RRUUY1a3loX0dvaThBMUZyc00wOXV1WXFrV2RSYjlod2FfTTIwbG5CMXZDY0hsckhROVM4NzVfdDh4NjhfdWxBUWdlQmJudjQ?oc=5","date":"2025-07-08","type":"regulatory","source":"Stock Titan","summary":"Rare Disease Expert Dr. Jay Backstrom Brings Regulatory Success to Agios Board at Critical Growth Phase - Stock Titan","headline":"Rare Disease Expert Dr. Jay Backstrom Brings Regulatory Success to Agios Board at Critical Growth Phase","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwJBVV95cUxNc2FVWEFnMEhoRmtlelJOLUN3RDhlYVVUZlNneFc0VENHeHFwcE5ELWFXSkRmaUdpYm9yN1d4VGVNcDNLTkw2NElvQzBRTXdkSzVCYkVLYTVoZEdFOWZBeVhiZnQ3cHQ3VTBXeEt3Z0ZZWEVuOEVQcUxvdzRreFNOMEtqbzNHdEtrakQyQkVLT1hLTVpGa3E1ZmFwNEJLYk15M2pqcnN2My12ekx0bklFaVAtamJXR3lfN213dmp4RFZucE1xdFkyUm8zNEtkVW5na2lqbmxfdVZDTUVPQTY4NWtCZzlxUWVyOFdpSUFJbEVxcGtmVXpuS2V5QlB2MlJYeUhxaUFHekR0U0hPd2Jwdm9iNzJlenlBSkpfdnhYZXA3bzdQRGxJ?oc=5","date":"2025-04-28","type":"trial","source":"Business Wire","summary":"Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth - Business Wire","headline":"Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale ","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2018-12-31","revenueHistory":[{"value":0,"period":"2018-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":208440000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-377939000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":323527000,"cashHistory":[],"totalAssets":404272000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}